- Indication
- VTE prophylaxis following hip and knee surgery
- RAG rating
- Red
- Document type
- n/a
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
DOAC (best value DOAC - 1st line generic apixaban & rivaroxaban)
HWE ICS first line choices on direct acting oral anticoagulant DOACs
- Generic prescribing apixaban for twice daily dosing regimen
- Generic prescribing rivaroxaban for once daily dosing regimen
- In the absence of specific patient characteristics determining choice, least expensive appropriate DOAC is to be used.
for the indications listed below:
Treatment for non-valvular atrial fibrillation (AF)
(Guidelines for oral anticoagulation of patients with non-valvular atrial fibrillation to prevent stroke in adults – click here)
Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent DVT and PE
Primary prevention of venous thromboembolic events in patients who have had hip or knee replacement surgery
All DOAC options (apixaban, edoxaban, rivaroxaban and dabigatran) are available in line with the recommendations from respective published NICE TA’s for above indications.
- Version number
- 2.0
- Developed by
- Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
- Approved by
- Hertfordshire & West Essex Area Prescribing Committee
- Date approved / updated
- November 2024
- Review date
- This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
- Superseded version
- Version 1.0 November 2023 Apixaban (generic 1st line)